日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial

接受强化治疗或克拉屈滨治疗的急性髓系白血病老年患者的生存情况:E2906 III期试验

Foran, James M; Sun, Zhuoxin; Luger, Selina M; Claxton, David F; Lazarus, Hillard M; Arber, Daniel A; Rowe, Jacob M; Paietta, Elisabeth; Racevskis, Janis; Garrett-Bakelman, Fran; Zhang, Yanming; Altman, Jessica K; Al-Kali, Aref; Zheng, Hong; Pratz, Keith W; Broun, E Randolph; Powell, Bayard L; O'Dwyer, Kristen Marie; Godwin, John E; Ofran, Yishai; Litzow, Mark R; Tallman, Martin S

Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features

B细胞急性淋巴细胞白血病的多能谱系潜能与不同的细胞起源和临床特征相关。

Iacobucci, Ilaria; Zeng, Andy G X; Gao, Qingsong; Garcia-Prat, Laura; Baviskar, Pradyumna; Shah, Sayyam; Murison, Alex; Voisin, Veronique; Chan-Seng-Yue, Michelle; Cheng, Cheng; Qu, Chunxu; Bailey, Colin; Lear, Matthew; Witkowski, Matthew T; Zhou, Xin; Zaldivar Peraza, Airen; Gangwani, Karishma; Advani, Anjali S; Luger, Selina M; Litzow, Mark R; Rowe, Jacob M; Paietta, Elisabeth M; Stock, Wendy; Dick, John E; Mullighan, Charles G

Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia - the CONS

急性髓系白血病首次复发后不久进行造血干细胞移植——CONS

Ofran, Yishai; Rowe, Jacob M

Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction

患有急性髓系白血病 (AML) 且携带 IDH2-R172 突变的患者对强化化疗诱导治疗表现出独特的初始反应。

Yisraeli Salman, Meira; Terry, Alexander R; Derkach, Andriy; Nemirovsky, David; Chin, Kuo-Kai; Valtis, Yannis K; Boussi, Leora; Spivey, Theresa; Xiao, Wenbin; Famulare, Christopher; Ciervo, Jenna; Rowe, Jacob M; Tallman, Martin S; Stein, Eytan M

Correction: Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study

更正:胎盘扩增间充质样细胞(PLX-R18)治疗造血干细胞移植后移植物功能不良:一项 I 期研究

McGuirk, Joseph P; Metheny, Leland 3rd; Pineiro, Luis; Litzow, Mark; Rowley, Scott D; Avni, Batia; Tamari, Roni; Lazarus, Hillard M; Rowe, Jacob M; Sheleg, Michal; Rothenstein, Daniel; Halevy, Nitsan; Zuckerman, Tsila

CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study

CPX-351 +/- 吉妥珠单抗奥佐米星作为新诊断的、预后良好至中等风险、FLT3-ITD 阴性急性髓系白血病 (AML) 成人患者的诱导治疗:一项初步研究

Ganzel, Chezi; Frisch, Avraham; Wolach, Ofir; Moshe, Yakir; Krayem, Baher; Dor, Neta; Broide, Etti; Benayoun, Emmanuel; Rowe, Jacob M; Ofran, Yishai

Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults

Blinatumomab 用于治疗成人 MRD 阴性急性淋巴细胞白血病

Litzow, Mark R; Sun, Zhuoxin; Mattison, Ryan J; Paietta, Elisabeth M; Roberts, Kathryn G; Zhang, Yanming; Racevskis, Janis; Lazarus, Hillard M; Rowe, Jacob M; Arber, Daniel A; Wieduwilt, Matthew J; Liedtke, Michaela; Bergeron, Julie; Wood, Brent L; Zhao, Yaqi; Wu, Gang; Chang, Ti-Cheng; Zhang, Wenchao; Pratz, Keith W; Dinner, Shira N; Frey, Noelle; Gore, Steven D; Bhatnagar, Bhavana; Atallah, Ehab L; Uy, Geoffrey L; Jeyakumar, Deepa; Lin, Tara L; Willman, Cheryl L; DeAngelo, Daniel J; Patel, Shejal B; Elliott, Michelle A; Advani, Anjali S; Tzachanis, Dimitrios; Vachhani, Pankit; Bhave, Rupali R; Sharon, Elad; Little, Richard F; Erba, Harry P; Stone, Richard M; Luger, Selina M; Mullighan, Charles G; Tallman, Martin S

Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk.

儿童 Gamma Delta T-ALL 的生物学和临床分析表明 LMO2/STAG2 重排具有极高风险

Kimura Shunsuke, Park Chun Shik, Montefiori Lindsey E, Iacobucci Ilaria, Pölönen Petri, Gao Qingsong, Arnold Elizabeth D, Attarbaschi Andishe, Brown Anthony, Buldini Barbara, Caldwell Kenneth J, Chang Yunchao, Chen Chelsey, Cheng Cheng, Cheng Zhongshan, Choi John, Conter Valentino, Crews Kristine R, de Groot-Kruseman Hester A, Deguchi Takao, Eguchi Mariko, Muhle Hannah E, Elitzur Sarah, Escherich Gabriele, Freeman Burgess B 3rd, Gu Zhaohui, Han Katie, Horibe Keizo, Imamura Toshihiko, Jeha Sima, Kato Motohiro, Chiew Kean H, Khan Tanya, Kicinski Michal, Köhrer Stefan, Kornblau Steven M, Kotecha Rishi S, Li Chi-Kong, Liu Yen-Chun, Locatelli Franco, Luger Selina M, Paietta Elisabeth M, Manabe Atsushi, Marquart Hanne V, Masetti Riccardo, Maybury Mellissa, Mazilier Pauline, Meijerink Jules P P, Mitchell Sharnise, Miyamura Takako, Moore Andrew S, Oshima Koichi, Pawinska-Wasikowska Katarzyna, Pieters Rob, Prater Mollie S, Pruett-Miller Shondra M, Pui Ching-Hon, Qu Chunxu, Reiterova Michaela, Reyes Noemi, Roberts Kathryn G, Rowe Jacob M, Sato Atsushi, Schmiegelow Kjeld, Schrappe Martin, Shen Shuhong, Skoczeń Szymon, Spinelli Orietta, Stary Jan, Svaton Michael, Takagi Masatoshi, Takita Junko, Tang Yanjing, Teachey David T, Thomas Paul G, Tomizawa Daisuke, Trka Jan, Varotto Elena, Vincent Tiffaney L, Yang Jun J, Yeoh Allen E J, Zhou Yinmei, Zimmermann Martin, Inaba Hiroto, Mullighan Charles G

Chimeric antigen receptor therapy for T-cell acute lymphoblastic leukemia: finally catching up with B-cell leukemia?

嵌合抗原受体疗法治疗T细胞急性淋巴细胞白血病:终于赶上B细胞白血病了吗?

Beyar-Katz, Ofrat; Rowe, Jacob M

What Influences the Decision to Proceed to Transplant for Patients With AML in First Remission?

影响急性髓系白血病(AML)患者首次缓解期是否进行移植的决定因素是什么?

DeWolf, Susan; Tallman, Martin S; Rowe, Jacob M; Salman, Meira Yisraeli